Novaremed AG is developing NRD.E1, an orally active non-opioid small molecule targeting painful diabetic peripheral neuropathy (PDPN) through a novel mechanism that decreases phosphorylation of Lyn kinase, critical for pain processing. The company addresses the high unmet need for effective pain relief alternatives to opioids, particularly for patients suffering from chronic neuropathic pain associated with diabetes and chemotherapy.
Funding
$50M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Painful diabetic peripheral neuropathy (PDPN) and chemotherapy-induced peripheral neuropathy (CIPN) are common and debilitating conditions with limited effective and safe treatment options, leading to a high unmet need for non-opioid alternatives. Current treatments often fail to provide adequate pain relief or are poorly tolerated, with many carrying risks of abuse, dependence, and withdrawal symptoms. The increasing prevalence of diabetes and cancer further exacerbates the need for innovative therapies.
Solution
Novaremed is developing a pipeline of non-opioid therapies targeting peripheral neuropathy and neuropathic pain. Their lead product, NRD.E1, is an orally available small molecule being developed as a replacement for opioids in the treatment of PDPN. NRD.E1 has a novel mechanism of action, decreasing phosphorylation of Lyn kinase, which is critical for pain processing in the central nervous system. The company is also developing MP-101 for the prevention of CIPN, and MP-103 for CIPN and other peripheral neuropathy indications; both are orally active combination products containing glutamate signaling modulators.
Target Audience
The primary target audience includes patients suffering from painful diabetic peripheral neuropathy (PDPN) and chemotherapy-induced peripheral neuropathy (CIPN), as well as healthcare providers seeking effective and safe non-opioid treatment options.
Features
- NRD.E1: Orally available, non-opioid small molecule targeting PDPN, currently in Phase 2b clinical trials supported by the NIH HEAL initiative.
- NRD.E1's mechanism of action decreases phosphorylation of Y-507 of Lyn kinase, involved in upregulation of the purinergic receptor P2X4.
- MP-101: Orally active combination product containing racemic dimiracetam and its R-enantiomer, being developed for the prevention of CIPN.
- MP-101 modulates glutamate signaling, a novel mechanism of action for CIPN treatment.
- MP-103: Orally active combination product containing the glutamate signaling modulators NT-24336 (R-enantiomer) and its S-enantiomer (NT-24781).
- FDA Fast Track Designation for NRD.E1 in the treatment of PDPN.